The warning from the FDA has been issued in conjunction with Novartis about its 2 injectable products, pamidronate (Aredia) and zoledronic acid (Zometa), both of which are used in cancer patients for ...

Bisphosphonates are medications that used to treat bone loss and are the most common agent to be prescribed for osteoporosis. These drugs can also reduce fracture risk in cases of previous fracture.

Bisphosphanates are used primarily for the prevention and treatment of osteoporosis, and are also indicated for osseous complications of malignancy. In addition to their bone resorption properties, ...

CRPS has been known by many different names, and diagnostic criteria have evolved over time. As no gold-standard diagnostic test exists, CRPS is evaluated on the phenotypic clinical presentation ...

Compared with oral bisphosphonates, denosumab reduced fracture risk among treatment-experienced postmenopausal women with osteoporosis. Treatment with denosumab vs oral bisphosphonates is associated ...

Bisphosphonates, long used to strengthen bones, may prevent recurrence of early-stage breast cancer in postmenopausal women. In a way, developing low bone-mineral density may have been a lucky break ...

Please provide your email address to receive an email when new articles are posted on . NASHVILLE, Tenn. — Treatment with bisphosphonates does not always lead to a decrease in fracture rates among ...

Long-term use of osteoporosis drugs seems to change bones in a way that could lead to unusual leg fractures, according to two reports presented at a meeting of orthopedic surgeons. Doctors have ...

BROOKLYN, NY — Authors of a new analysis say the US Food and Drug Administration (FDA) should consider revisiting its investigation of the atrial-fibrillation (AF) risk with certain osteoporosis drugs ...

Long-term bisphosphonate therapy can change bones at the microscopic level to make them more susceptible to the rare catastrophic transverse breaks known as atypical femoral fractures (AFFs), ...

Please provide your email address to receive an email when new articles are posted on . In an update to its guidance on primary osteoporosis, ACP recommended bisphosphonates as a first line of defense ...

The relative risk of an atypical femoral fracture with bisphosphonate use related to duration of therapy, with the highest risks being seen after 5 years of exposure, a nationwide study in Denmark ...